{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:11:30Z","timestamp":1788498690599,"version":"build-2803163510"},"reference-count":42,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute Cancer Center Support","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Cushing\u2019s syndrome (CS) impairs quality of life (QoL) and mood. Prospective real-life data on posttreatment recovery and predictors of improvement are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Evaluate changes in QoL, depression, and anxiety in patients with CS, before and after biochemical control, and identify predictors of clinically meaningful improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Setting<\/jats:title>\n                    <jats:p>Prospective observational study at a tertiary center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Sixty-seven patients with endogenous CS (60 pituitary, 7 adrenal) were assessed with active disease and again after achieving biochemical control through surgery and\/or medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Patient-reported outcomes included CushingQoL, Beck Depression Inventory-II (BDI-II), and State-Trait Anxiety Inventory (STAI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean and longest follow-up was 2.3 and 11.5 years, respectively. Treatment led to improvements in mean scores across all domains (QoL: +18.2 \u00b1 20.9, BDI-II: \u22126.8 \u00b1 8.6, STAI-State: \u22129.6 \u00b1 12.5, STAI-Trait: \u22128.6 \u00b1 12.6; all P &amp;lt; .001). However, a minimal important difference was achieved in 64.6% for QoL, 67.9% for BDI-II, and 53.2% and 52.8% for STAI subscales. After multivariable analysis, QoL improvements were predicted by lower baseline body mass index, pretreatment symptoms &amp;lt;3 years, postoperative hydrocortisone replacement &amp;gt;6 months, and normal follow-up late-night salivary cortisol (LNSC). Depression improvements were predicted by symptoms &amp;lt;3 years, normal follow-up LNSC, and surgical treatment. Anxiety improvements were predicted by younger age and &amp;gt;6 months postoperative hydrocortisone. Depression improved more gradually than QoL and anxiety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although effective treatment improves mood and QoL in CS, clinically meaningful recovery is variable and incomplete for some patients. Our findings highlight the need to limit diagnostic delay and provide comprehensive posttreatment care that includes normalization of cortisol circadian rhythm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf598","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:21:23Z","timestamp":1761830483000},"page":"e1396-e1411","source":"Crossref","is-referenced-by-count":9,"title":["Prospective Assessment of Mood and Quality of Life in Cushing Syndrome Before and After Biochemical Control"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-7250","authenticated-orcid":false,"given":"Angeliki","family":"Theodorou","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5668-9699","authenticated-orcid":false,"given":"Emily C","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A","family":"Bakkar","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1258-6112","authenticated-orcid":false,"given":"Anne S","family":"Reiner","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sazo","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-7967","authenticated-orcid":false,"given":"Marc A","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]},{"name":"Department of Neurosurgery, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]},{"name":"Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-261X","authenticated-orcid":false,"given":"Andrew L","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]},{"name":"Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-1670","authenticated-orcid":false,"given":"Viviane","family":"Tabar","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]},{"name":"Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3722-1889","authenticated-orcid":false,"given":"Eliza B","family":"Geer","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]},{"name":"Department of Neurosurgery, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]},{"name":"Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"9258","key":"2026042119580351800_dgaf598-B1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(00)04172-6","article-title":"Cushing's syndrome","volume":"357","author":"Boscaro","year":"2001","journal-title":"The Lancet"},{"issue":"12","key":"2026042119580351800_dgaf598-B2","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing's syndrome: a consensus statement","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026042119580351800_dgaf598-B3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-11-1095","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: the burden of Cushing's disease: clinical and health-related quality of life aspects","volume":"167","author":"Feelders","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026042119580351800_dgaf598-B4","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1210\/jc.2004-1375","article-title":"Quality of life in patients after long-term biochemical cure of Cushing's disease","volume":"90","author":"van Aken","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026042119580351800_dgaf598-B5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2265.2004.02118.x","article-title":"Long-term negative impact on quality of life in patients with successfully treated Cushing's disease","volume":"61","author":"Heald","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026042119580351800_dgaf598-B6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2265.2006.02462.x","article-title":"Personality characteristics and quality of life in patients treated for Cushing's syndrome","volume":"64","author":"Sonino","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026042119580351800_dgaf598-B7","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s11102-024-01450-8","article-title":"Sleep disruption in patients with active and treated endogenous Cushing's syndrome","volume":"27","author":"Geer","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"2026042119580351800_dgaf598-B8","first-page":"912","article-title":"The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism","volume":"82","author":"Dorn","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026042119580351800_dgaf598-B9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3171\/2019.8.JNS19930","article-title":"Cushing's disease: a prospective case-control study of health-related quality of life and cognitive status before and after surgery","volume":"133","author":"Zarino","year":"2020","journal-title":"J Neurosurg"},{"key":"2026042119580351800_dgaf598-B10","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3389\/fendo.2019.00862","article-title":"Quality of life in patients with Cushing's disease","volume":"10","author":"Santos","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026042119580351800_dgaf598-B11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13023-018-0958-4","article-title":"Illustration of patient-reported outcome challenges and solutions in rare diseases: a systematic review in Cushing's syndrome","volume":"13","author":"Knoble","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"2026042119580351800_dgaf598-B12","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1210\/jc.2019-00749","article-title":"Hippocampal volume, cognitive functions, depression, anxiety, and quality of life in patients with cushing syndrome","volume":"104","author":"Frimodt-M\u00f8ller","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026042119580351800_dgaf598-B13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1210\/edrv.31.4.9976","article-title":"Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease","volume":"31","author":"Tiemensma","year":"2010","journal-title":"Endocr Rev"},{"key":"2026042119580351800_dgaf598-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocn.2019.05.059","article-title":"Posttraumatic stress symptoms (PTSS) in patients with Cushing's disease before and after surgery: a prospective study","volume":"66","author":"Chen","year":"2019","journal-title":"J Clin Neurosci"},{"key":"2026042119580351800_dgaf598-B15","doi-asserted-by":"crossref","first-page":"2061935","DOI":"10.1155\/2017\/2061935","article-title":"Depression and anxiety scores are associated with amygdala volume in Cushing's syndrome: preliminary study","volume":"2017","author":"Santos","year":"2017","journal-title":"Biomed Res Int"},{"issue":"1","key":"2026042119580351800_dgaf598-B16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11102-020-01103-6","article-title":"Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome","volume":"24","author":"Geer","year":"2021","journal-title":"Pituitary"},{"issue":"1","key":"2026042119580351800_dgaf598-B17","doi-asserted-by":"crossref","first-page":"bvae201","DOI":"10.1210\/jendso\/bvae201","article-title":"Improved clinical outcomes during long-term osilodrostat treatment of Cushing's disease with LNSC and UFC normalization","volume":"9","author":"Newell-Price","year":"2024","journal-title":"J Endocr Soc"},{"issue":"3","key":"2026042119580351800_dgaf598-B18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","article-title":"Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a phase III study","volume":"81","author":"Pivonello","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026042119580351800_dgaf598-B19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-13-1013","article-title":"Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease","volume":"171","author":"Webb","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026042119580351800_dgaf598-B20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.32598\/jhnm.33.2.2341","article-title":"Comparing quality of life before and after surgery in patients with cushing disease: a before-after study","volume":"33","author":"Chouhdari","year":"2023","journal-title":"J Holist Nurs Midwifery"},{"key":"2026042119580351800_dgaf598-B21","doi-asserted-by":"crossref","first-page":"1236465","DOI":"10.3389\/fendo.2023.1236465","article-title":"Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension","volume":"14","author":"Gadelha","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026042119580351800_dgaf598-B22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40271-013-0012-5","article-title":"Psychometric evaluation of the Cushing's quality-of-life questionnaire","volume":"6","author":"Nelson","year":"2013","journal-title":"Patient"},{"issue":"5","key":"2026042119580351800_dgaf598-B23","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026042119580351800_dgaf598-B24","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026042119580351800_dgaf598-B25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026042119580351800_dgaf598-B26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0762","article-title":"Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire","volume":"158","author":"Webb","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2026042119580351800_dgaf598-B27","doi-asserted-by":"publisher","author":"Dozois","DOI":"10.1002\/9780470479216.corpsy0113"},{"issue":"10","key":"2026042119580351800_dgaf598-B28","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1017\/S0033291720003700","article-title":"How much change is enough? Evidence from a longitudinal study on depression in UK primary care","volume":"52","author":"Kounali","year":"2022","journal-title":"Psychol Med"},{"key":"2026042119580351800_dgaf598-B29","doi-asserted-by":"publisher","author":"Skapinakis","DOI":"10.1007\/978-94-007-0753-5_2825"},{"key":"2026042119580351800_dgaf598-B30","unstructured":"Theodorou A, Tan EC, Bakkar MA, et al \u00a0Data from: JCEM Supplementary Table: PROs mean scores and pairwise comparisons in patients with two follow-up visits. Figshare. doi:10.6084\/m9.figshare.30200602.v2. Published September 24, 2025."},{"issue":"3","key":"2026042119580351800_dgaf598-B31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/cen.12521","article-title":"Predictors of quality of life in 102 patients with treated Cushing's disease","volume":"82","author":"Carluccio","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026042119580351800_dgaf598-B32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1530\/EJE-12-0308","article-title":"Impaired quality of life in patients in long-term remission of Cushing's syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism?","volume":"167","author":"Wagenmakers","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026042119580351800_dgaf598-B33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1530\/EJE-16-0779","article-title":"Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels","volume":"176","author":"Valassi","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026042119580351800_dgaf598-B34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.endonu.2013.03.008","article-title":"Prognosis of patients treated for Cushing syndrome","volume":"61","author":"Aulinas","year":"2014","journal-title":"Endocrinol Nutr"},{"issue":"6","key":"2026042119580351800_dgaf598-B35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s11102-016-0750-1","article-title":"Coping strategies have a strong impact on quality of life, depression, and embitterment in patients with Cushing's disease","volume":"19","author":"Siegel","year":"2016","journal-title":"Pituitary"},{"issue":"2","key":"2026042119580351800_dgaf598-B36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/jc.2005-1058","article-title":"Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission","volume":"91","author":"Lindsay","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026042119580351800_dgaf598-B37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1530\/EJE-12-0325","article-title":"Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice","volume":"167","author":"Santos","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026042119580351800_dgaf598-B38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4103\/ijem.ijem_314_23","article-title":"An integrated clinical score to predict remission in Cushing's disease","volume":"27","author":"Gupta","year":"2023","journal-title":"Indian J Endocrinol Metab"},{"issue":"8","key":"2026042119580351800_dgaf598-B39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.endonu.2012.09.009","article-title":"Factores pron\u00f3sticos de remisi\u00f3n a largo plazo tras cirug\u00eda transesfenoidal en la enfermedad de Cushing (predictors of long-term remission after transsphenoidal surgery in Cushing's disease)","volume":"60","author":"Abell\u00e1n Galiana","year":"2013","journal-title":"Endocrinol Nutr"},{"issue":"1","key":"2026042119580351800_dgaf598-B40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41398-020-00980-6","article-title":"Cortical thickness abnormalities in long-term remitted Cushing's disease","volume":"10","author":"Bauduin","year":"2020","journal-title":"Transl Psychiatry"},{"issue":"S11","key":"2026042119580351800_dgaf598-B41","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1002\/acr.20561","article-title":"Measures of anxiety: state-trait anxiety inventory (STAI), beck anxiety inventory (BAI), and hospital anxiety and depression scale-anxiety (HADS-A)","volume":"63","author":"Julian","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"2026042119580351800_dgaf598-B42","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11102-017-0793-y","article-title":"White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study","volume":"20","author":"Pires","year":"2017","journal-title":"Pituitary"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf598\/65044238\/dgaf598.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/e1396\/65044238\/dgaf598.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/e1396\/65044238\/dgaf598.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:58:12Z","timestamp":1776815892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/5\/e1396\/8307075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf598","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,10,31]]}}}